Overview Dividends

(SOLV) Solventum - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US83444M1018

Wound Therapy, Dental Products, Medical Software, Filtration

SOLV EPS (Earnings per Share)

EPS Growth (3Y CAGR): -21.87%
EPS Trend (3Y Correlation): -56.5%

SOLV Revenue

Revenue Growth (3Y CAGR): 2.28%
Revenue Trend (3Y Correlation): 70.4%

Risk via 10d forecast
Volatility	31.1%
Value at Risk 5%th	48.0%
Relative Tail Risk	-5.99%

Reward TTM
Sharpe Ratio	0.27
Alpha	-6.03

Character TTM
Hurst Exponent	0.385
Beta	0.908
Beta Downside	1.039

Drawdowns 3y
Max DD	39.97%
Mean DD	16.31%
Median DD	14.01%

Description: SOLV Solventum October 30, 2025

Solventum Corp. (NYSE:SOLV) is a newly-public healthcare-equipment company headquartered in Maplewood, Minnesota, that markets a diversified product suite across four segments: Medsurg (negative-pressure wound therapy, dressings, I.V. site management, etc.), Dental Solutions (brackets, aligners, cements), Health Information Systems (clinical documentation, coding automation, speech-recognition tools), and Purification & Filtration (filters, cartridges, membranes). Its go-to-market model blends direct-to-consumer, distribution, key-account, inside-sales, and e-commerce channels.

In the most recent quarter (Q2 2024), SOLV reported revenue of roughly $85 million, a year-over-year increase of about 12%, and a gross margin near 38%, reflecting the higher-margin nature of its wound-care and dental-orthodontic lines. The company’s backlog-primarily driven by long-term supply contracts for wound-therapy kits-stood at an estimated $150 million, providing a near-term visibility cushion.

Key macro drivers for SOLV include the U.S. aging demographic, which is expanding the demand for advanced wound-care and home-based medical supplies, and a 4% annual growth in U.S. healthcare spending that supports incremental adoption of its health-information software. Additionally, the dental-orthodontics market is projected to grow 6% CAGR through 2028, buoyed by rising consumer willingness to invest in cosmetic dental solutions.

For a deeper, data-driven valuation and scenario analysis, you may find ValueRay’s platform worth a look.

SOLV Stock Overview

Market Cap in USD	13,123m
Sub-Industry	Health Care Equipment
IPO / Inception	2024-03-26
Return 12m vs S&P 500	-2.52%
Analyst Rating	3.25 of 5

SOLV Dividends

Currently no dividends paid

SOLV Growth Ratios

CAGR 3y	-3.35%
CAGR/Max DD Calmar Ratio	-0.08
CAGR/Mean DD Pain Ratio	-0.21
Current Volume	1053.8k
Average Volume	836.7k

Piotroski VR‑10 (Strict, 0-10) 4.5

Net Income (1.52b TTM) > 0 and > 6% of Revenue (6% = 504.1m TTM)

FCFTA 0.00 (>2.0%) and ΔFCFTA -7.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 17.48% (prev 5.44%; Δ 12.05pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 493.0m <= Net Income 1.52b (YES >=105%, WARN >=100%)

Net Debt (3.50b) to EBITDA (2.59b) ratio: 1.35 <= 3.0 (WARN <= 3.5)

Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (175.4m) change vs 12m ago 0.86% (target <= -2.0% for YES)

Gross Margin 54.57% (prev 55.46%; Δ -0.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 58.51% (prev 56.11%; Δ 2.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.14 (EBITDA TTM 2.59b / Interest Expense TTM 403.0m) >= 6 (WARN >= 3)

Altman Z'' 2.20

(A) 0.11 = (Total Current Assets 4.41b - Total Current Liabilities 2.94b) / Total Assets 13.97b

(B) 0.12 = Retained Earnings (Balance) 1.73b / Total Assets 13.97b

(D) 0.13 = Book Value of Equity 1.13b / Total Liabilities 8.99b

Total Rating: 2.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.86

1. Piotroski 4.50pt = -0.50

2. FCF Yield 0.30% = 0.15

3. FCF Margin 0.60% = 0.15

4. Debt/Equity 1.03 = 1.99

5. Debt/Ebitda 1.35 = 1.23

6. ROIC - WACC (= 8.71)% = 10.88

7. RoE 41.04% = 2.50

8. Rev. Trend 70.42% = 5.28

9. EPS Trend -56.50% = -2.83

What is the price of SOLV shares?

As of November 17, 2025, the stock is trading at USD 75.66 with a total of 1,053,840 shares traded.
Over the past week, the price has changed by +5.39%, over one month by +5.91%, over three months by +6.92% and over the past year by +12.72%.

Is Solventum a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Solventum (NYSE:SOLV) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.86 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SOLV is around 68.51 USD . This means that SOLV is currently overvalued and has a potential downside of -9.45%.

Is SOLV a buy, sell or hold?

Solventum has received a consensus analysts rating of 3.25. Therefor, it is recommend to hold SOLV.

Strong Buy: 1
Buy: 2
Hold: 8
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the SOLV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	84.1	11.2%
Analysts Target Price	84.1	11.2%
ValueRay Target Price	75.5	-0.3%

SOLV Fundamental Data Overview November 16, 2025

Market Cap USD = 13.12b (13.12b USD * 1.0 USD.USD)
P/E Trailing = 8.6866
P/E Forward = 12.0773
P/S = 1.5619
P/B = 2.632
Beta = None
Revenue TTM = 8.40b USD
EBIT TTM = 2.07b USD
EBITDA TTM = 2.59b USD
Long Term Debt = 5.14b USD (from longTermDebt, last quarter)
Short Term Debt = 200.0m USD (from shortTermDebt, last fiscal year)
Debt = 5.14b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 3.50b USD (from netDebt column, last quarter)
Enterprise Value = 16.62b USD (13.12b + Debt 5.14b - CCE 1.64b)
Interest Coverage Ratio = 5.14 (Ebit TTM 2.07b / Interest Expense TTM 403.0m)
FCF Yield = 0.30% (FCF TTM 50.0m / Enterprise Value 16.62b)
FCF Margin = 0.60% (FCF TTM 50.0m / Revenue TTM 8.40b)
Net Margin = 18.14% (Net Income TTM 1.52b / Revenue TTM 8.40b)
Gross Margin = 54.57% ((Revenue TTM 8.40b - Cost of Revenue TTM 3.82b) / Revenue TTM)
Gross Margin QoQ = 56.15% (prev 54.37%)
Tobins Q-Ratio = 1.19 (Enterprise Value 16.62b / Total Assets 13.97b)
Interest Expense / Debt = 1.73% (Interest Expense 89.0m / Debt 5.14b)
Taxrate = 16.38% (248.0m / 1.51b)
NOPAT = 1.73b (EBIT 2.07b * (1 - 16.38%))
Current Ratio = 1.50 (Total Current Assets 4.41b / Total Current Liabilities 2.94b)
Debt / Equity = 1.03 (Debt 5.14b / totalStockholderEquity, last quarter 4.99b)
Debt / EBITDA = 1.35 (Net Debt 3.50b / EBITDA 2.59b)
Debt / FCF = 69.90 (Net Debt 3.50b / FCF TTM 50.0m)
Total Stockholder Equity = 3.71b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.91% (Net Income 1.52b / Total Assets 13.97b)
RoE = 41.04% (Net Income TTM 1.52b / Total Stockholder Equity 3.71b)
RoCE = 23.40% (EBIT 2.07b / Capital Employed (Equity 3.71b + L.T.Debt 5.14b))
RoIC = 15.84% (NOPAT 1.73b / Invested Capital 10.93b)
WACC = 7.13% (E(13.12b)/V(18.26b) * Re(9.36%) + D(5.14b)/V(18.26b) * Rd(1.73%) * (1-Tc(0.16)))
Discount Rate = 9.36% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 0.29%
[DCF Debug] Terminal Value 65.78% ; FCFE base≈498.8m ; Y1≈341.4m ; Y5≈169.7m
Fair Price DCF = 15.40 (DCF Value 2.67b / Shares Outstanding 173.4m; 5y FCF grow -36.93% → 3.0% )
EPS Correlation: -56.50 | EPS CAGR: -21.87% | SUE: -0.28 | # QB: 0
Revenue Correlation: 70.42 | Revenue CAGR: 2.28% | SUE: 2.14 | # QB: 2

Additional Sources for SOLV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle